Published on in Vol 3, No 4 (2017): Oct-Dec

Viral Hepatitis Strategic Information to Achieve Elimination by 2030: Key Elements for HIV Program Managers

Viral Hepatitis Strategic Information to Achieve Elimination by 2030: Key Elements for HIV Program Managers

Viral Hepatitis Strategic Information to Achieve Elimination by 2030: Key Elements for HIV Program Managers

Journals

  1. Nguyen M, Wong G, Gane E, Kao J, Dusheiko G. Hepatitis B Virus: Advances in Prevention, Diagnosis, and Therapy. Clinical Microbiology Reviews 2020;33(2) View
  2. Behzadifar M, Gorji H, Rezapour A, Bragazzi N. The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon’s multiple streams framework. Health Research Policy and Systems 2019;17(1) View
  3. Reiser M, Wiebner B, Hirsch J. Neural-network analysis of socio-medical data to identify predictors of undiagnosed hepatitis C virus infections in Germany (DETECT). Journal of Translational Medicine 2019;17(1) View
  4. Cheng C, Feng C, Chua C. Help-Seeking Experiences of Hepatitis B Patients in Transnational Medical Care: The Solution to Health Inequality Is Social Mobility. Healthcare 2019;7(4):125 View
  5. Mårdh O, Quinten C, Amato-Gauci A, Duffell E. Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA – descriptive analysis and estimation of 2015 baseline. Infectious Diseases 2020;52(9):625 View
  6. Rice B, Sanchez T, Baral S, Mee P, Sabin K, Garcia-Calleja J, Hargreaves J. Know Your Epidemic, Strengthen Your Response: Developing a New HIV Surveillance Architecture to Guide HIV Resource Allocation and Target Decisions. JMIR Public Health and Surveillance 2018;4(1):e18 View
  7. Pedrana A, Howell J, Scott N, Schroeder S, Kuschel C, Lazarus J, Atun R, Baptista-Leite R, 't Hoen E, Hutchinson S, Aufegger L, Peck R, Sohn A, Swan T, Thursz M, Lesi O, Sharma M, Thwaites J, Wilson D, Hellard M. Global hepatitis C elimination: an investment framework. The Lancet Gastroenterology & Hepatology 2020;5(10):927 View
  8. Behzadifar M, Gorji H, Rezapour A, Bragazzi N. Comparison of prevention, screening and treatment of hepatitis C in Iran, Egypt and Georgia. Journal of Virus Eradication 2019;5(2):116 View
  9. Applegate T, Fajardo E, Sacks J. Hepatitis C Virus Diagnosis and the Holy Grail. Infectious Disease Clinics of North America 2018;32(2):425 View
  10. Jefferies M, Rauff B, Rashid H, Lam T, Rafiq S. Update on global epidemiology of viral hepatitis and preventive strategies. World Journal of Clinical Cases 2018;6(13):589 View
  11. Howell J, Pedrana A, Schroeder S, Scott N, Aufegger L, Atun R, Baptista-Leite R, Hirnschall G, ‘t Hoen E, Hutchinson S, Lazarus J, Olufunmilayo L, Peck R, Sharma M, Sohn A, Thompson A, Thursz M, Wilson D, Hellard M. A global investment framework for the elimination of hepatitis B. Journal of Hepatology 2021;74(3):535 View
  12. Al Awaidy S, Ezzikouri S. Moving towards hepatitis B elimination in Gulf Health Council states: From commitment to action. Journal of Infection and Public Health 2020;13(2):221 View
  13. Li M, Wang Z, Zhang L, Zheng H, Zhou M, Liu D. Burden of viral hepatitis caused by specific aetiologies in China, 1990–2016: findings from the GBD 2016. BMC Public Health 2020;20(1) View
  14. Duffell E, Cortez‐Pinto H, Simonova M, Dalgard O, Dahl E, de Martel C, Mozalevskis A, Buti M, Pavlova S, Hadzhilova T, Simões C, Katzarov K, Mardh O. Estimating the attributable fraction of cirrhosis and hepatocellular carcinoma due to hepatitis B and C. Journal of Viral Hepatitis 2021;28(8):1177 View
  15. Alberts C, Clifford G, Georges D, Negro F, Lesi O, Hutin Y, de Martel C. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. The Lancet Gastroenterology & Hepatology 2022;7(8):724 View
  16. Flores E, Howell J. Bridging the gap to achieve viral hepatitis mortality targets. The Lancet Gastroenterology & Hepatology 2022;7(8):691 View
  17. Kalluri H, Oberoi R, Chen Q, Jiang Q, Asatryan A, Alami N, Yu C, Liu W. Pharmacokinetics, Tolerability, and Safety of Glecaprevir/Pibrentasvir Co‐formulated Bilayer Tablet Following Repeated Administration in Healthy Chinese Adults. Clinical Pharmacology in Drug Development 2023;12(10):945 View
  18. Howell J, Seaman C, Wallace J, Xiao Y, Scott N, Davies J, de Santis T, Adda D, El-Sayed M, Feld J, Gane E, Lacombe K, Lesi O, Mohamed R, Silva M, Tu T, Revill P, Hellard M. Pathway to global elimination of hepatitis B: HBV cure is just the first step. Hepatology 2023;78(3):976 View
  19. Holt B, Fernandez M, Nguyen D, Delima D, Duy L, Gaspar M, Hamoy G, Le B, Llevado J, Manlutac J, Mendoza J, Mercado T, Nguyen H, Nguyen H, Ong J, Rombaoa M, Florendo J, Dela Cruz J, Pham T, Thai P, Truong P, Pollack T, Duong D. Embedding viral hepatitis into primary healthcare: results of a strategic landscape analysis in Vietnam and the Philippines. The Lancet Regional Health - Western Pacific 2024;44:100990 View
  20. Tolulope Nejo Y, Oluwasemowo O, Ibidunni Ajao E, Odunayo Ajala M, Felicia Adedire O, Kingsley Adegbite I, Favour Esan B, Olajumoke Morakinyo O, Samuel Ibitoye A, Beauty Alade A. Serological profile of hepatitis B virus infection among traditional birth attendants and the attending pregnant women in Ibadan, Nigeria. Journal of Immunoassay and Immunochemistry 2024;45(3):247 View
  21. Salu O, Akinbamiro T, Orenolu R, Ishaya O, Anyanwu R, Vitowanu O, Abdullah M, Olowoyeye A, Tijani S, Oyedeji K, Omilabu S, Oluwayelu D. Detection of hepatitis viruses in suspected cases of Viral Haemorrhagic Fevers in Nigeria. PLOS ONE 2024;19(6):e0305521 View
  22. Kaushal K, Aggarwal P, Dahiya N, Kumar G. Impact of educational interventions on hepatitis B and C awareness among school students of Delhi NCR, India. BMC Public Health 2024;24(1) View

Books/Policy Documents

  1. Nath Chatterjee A, Al Basir F. Mathematical Analysis of Infectious Diseases. View
  2. Ward J, Wanlapakorn N, Poovorawan Y, Shouval D. Plotkin's Vaccines. View